Department of Health and Human Services (HHS)
On December 31st, NCCS submitted our final comment letter of the year to the Centers for Medicare and Medicaid Services regarding the advance notice of proposed rulemaking for the Medicare Part B drug program.

In the letter, we outlined concerns that this proposal could have on Medicare beneficiaries such as impacts on patient access to innovative therapies, as well as concerns regarding the enormous scope of the test. NCCS suggested a more modest test with aggressive evaluation standards. We also recommended that the new Part B test should be coordinated with the ongoing Oncology Care Model demonstration project.

“Although we fully understand the desire to address Medicare Part B, the potential to create disruption for Medicare beneficiaries is substantial. The scope of the test—in geographic areas that would include 50 percent of Medicare Part B spending on separately paid Part B drugs—is expansive. We identify below issues that we urge CMS to consider if moves ahead with a proposed rule in 2019 and implementation of the revised Part B program in 2020.”NCCS Comment Letter to CMS

NCCS also joined the Cancer Leadership Council in a letter regarding the proposal. Read the full NCCS and CLC letters below.


NCCS Letter to CMS

View/download the letter


Cancer Leadership Council Letter to CMS

View/download the letter


Read more NCCS Policy Comments »

Related Posts

Health Care Roundup: New Medicare Drug Pricing Proposal; New ACA Waiver Guidance; High Price of Precision Medicine; Midterms; More

NCCS “Not Persuaded” Drug Pricing in DTC Ads Will Improve Doctor-Patient Communication

Tagged with →